The discovery of monoclonal antibodies that neutralize Rift Valley Fever Virus — an emerging infection with pandemic potential — lays the foundation for future therapeutic antibody development.

Despite an impressive vaccination effort that exceeds 2 million shots a day, rates of COVID-19 are again on the rise in several parts of the United States, as is the spread of highly transmissible variants of the virus.

Vanderbilt’s Muktar Aliyu, MBBS, MPH, DrPH, and Hilary Tindle, MD, MPH, will be inducted this year into the American Society for Clinical Investigation (ASCI), an elite honor society of physician-scientists from the upper ranks of academic medicine and industry.

Vanderbilt University Medical Center is recruiting volunteers for a randomized controlled phase 2 clinical trial to help determine the prevalence of systemic allergic reactions (SARS) to the two-dose COVID-19 mRNA vaccines made by Pfizer-BioNTech and Moderna.

The U.S. Centers for Disease Control and Prevention (CDC) has awarded Vanderbilt University Medical Center a two-year, $3.7-million contract to determine genetic and bacterial factors that may increase the risk for severe illness and death from COVID-19.

Christine Cassel, MD, a leading expert in geriatric medicine, medical ethics and the quality of care, will deliver the next web-based Discovery Lecture on Thursday, March 25, at 4 p.m. via Zoom.